Skip to content
PaperFren

Diagnostic accuracy

Can a rapid test diagnose sickle cell at the bedside?

Kanter J, Telen MJ, Hoppe C, et al. · BMC medicine · 2015

Open access · cc by · source: Europe PMC

Sickle SCAN, a point-of-care immunoassay, was validated against laboratory gold standards for detecting hemoglobin S and related genotypes.

Key findings

The device could detect HbS and HbC at low percentages suitable for neonates, showed no interference from tested substances at stated concentrations, and was positioned to confirm sickle trait and common SCD genotypes rapidly.

Methodology

Researchers tested 137 patient blood samples in duplicate with Sickle SCAN and compared results to hemoglobin electrophoresis or HPLC, also measuring limits of detection and common interferents.

Limitations

Validation accuracy figures depend on the tested sample mix and lab settings; field performance in low-resource newborn screening programs needs separate evaluation.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • QualifiesDiagnostic Accuracyconcept

    A multiplex assay can identify Staphylococcus from blood cultures with very high accuracy.

    A multiplex molecular assay on monomicrobial blood cultures identified Staphylococcus at genus level with sensitivity about 99.4% and specificity about 99.7% in a large evaluated set.

    Scope note — different target — sickle-cell bedside detection, not blood-culture ID

    Limits the claim's scope: a different population, assay, or outcome.

  • SupportsDiagnostic Accuracyconcept

    Other tools (sickle cell, pain subtype, frailty trajectories) answer their own accuracy questions.

    Other validated tools in this set include a point-of-care sickle-cell device detecting HbS/HbC at low percentages suitable for neonates, StEP pinprick signs highly sensitive/specific for neuropathic vs non-neuropathic pain in specialist clinics, and rapidly rising electronic frailty index trajectories associated with doubled 12-month mortality versus stable frailty.

    Evidence for the claim as stated.

History

When this study was placed

Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.

  1. 2026-09-14

    Placed as a scope qualifier on Diagnostic Accuracy

    A multiplex molecular assay on monomicrobial blood cultures identified Staphylococcus at genus level with sensitivity about 99.4% and specificity about 99.7% in a large evaluated set.

  2. 2026-09-14

    Placed as supporting evidence on Diagnostic Accuracy

    Other validated tools in this set include a point-of-care sickle-cell device detecting HbS/HbC at low percentages suitable for neonates, StEP pinprick signs highly sensitive/specific for neuropathic vs non-neuropathic pain in specialist clinics, and rapidly rising electronic frailty index trajectories associated with doubled 12-month mortality versus stable frailty.

Related papers in this topic

Same topic cluster — not a recommendation engine.